Overview

ROXRO PHARMA, Inc. is a privately owned, virtually organized specialty pharmaceutical company focused on developing innovative treatments for pain.

Founded in 1999, ROXRO was one of the first pharmaceutical start-ups built upon the “virtual company” business model. Led by a highly experienced senior management team, ROXRO has assembled a global network of external experts to successfully bring its products through all aspects of development.

ROXRO is focused on treating acute pain so that patients can rapidly return to their normal lives. Our products include:

SPRIX™ (ketorolac tromethamine) Nasal Spray

ROX-828: Currently in Phase 2 clinical development, ROX-828 is an investigational alternative intranasal formulation of ketorolac for the treatment of migraine.

Important Safety Information About SPRIX

WARNING: LIMITATIONS OF USE, GASTROINTESTINAL, BLEEDING, CARDIOVASCULAR, and RENAL RISK

Limitations of Use – The total duration of use of SPRIX and other ketorolac formulations should not exceed 5 days.

Gastrointestinal (GI) Risk – Ketorolac can cause peptic ulcers, GI bleeding, and/or perforation of the stomach or intestines, which can be fatal. SPRIX is CONTRAINDICATED in patients with peptic ulcer disease or history of GI bleeding.

Bleeding Risk – SPRIX inhibits platelet function and is CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding.

Cardiovascular (CV) Risk – NSAIDs may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk. SPRIX is CONTRAINDICATED for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Renal Risk – SPRIX is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.

Mild, transient nasal discomfort was the most frequently reported side-effect of SPRIX use. SPRIX is contraindicated in patients with known hypersensitivity or a history of allergic reactions to aspirin, ketorolac, other NSAIDs or EDTA; in patients at risk for GI bleeding; prior to major surgery or during the perioperative period in CABG surgery; in patients with advanced renal disease or volume depletion; patients with certain bleeding risk and during labor and delivery. SPRIX should not be used concurrently with probenecid or pentoxifylline. Treat patients for the shortest duration possible, and do not exceed 5 days of therapy with SPRIX. See the full prescribing information for more details.